Rivaroxaban – Medxy AI

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

By MedXY 01/22/2026

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the trial was halted early for futility, highlighting the complexity of AF-related neurocognitive impairment.

Cardiology Neurology news

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

By MedXY 11/10/2025

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while numerically more major bleeding occurred with rivaroxaban.

Gastroenterology Internal Medicine news

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY 10/28/2025

The CIRROXABAN trial evaluates rivaroxaban's efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding risk.

Gastroenterology Internal Medicine news

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY 10/28/2025

Clinical Updates news

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY 09/27/2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research.

Cardiology Clinical Updates news Specialties

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY 09/22/2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Oncology Specialties

Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？

By MedXY 08/26/2025

An 18-month course of rivaroxaban significantly lowers recurrent venous thromboembolism compared to 6 months in cancer patients with low-risk pulmonary embolism without a substantial increase in major bleeding risk.

Cardiology Specialties

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial

By MedXY 08/17/2025

The ARIVA trial found no superior benefit of adding aspirin to rivaroxaban over rivaroxaban alone in preventing venous stent thrombosis within 6 months post-intervention in post-thrombotic syndrome patients, with both regimens showing high patency and safety.

Cardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY 08/16/2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.